134 related articles for article (PubMed ID: 10195630)
21. A vaccine composed of a hypothetical protein and the eukaryotic initiation factor 5a from Leishmania braziliensis cross-protection against Leishmania amazonensis infection.
Duarte MC; Lage DP; Martins VT; Costa LE; Carvalho AMRS; Ludolf F; Santos TTO; Vale DL; Roatt BM; Menezes-Souza D; Fernandes AP; Tavares CAP; Coelho EAF
Immunobiology; 2017 Feb; 222(2):251-260. PubMed ID: 27693018
[TBL] [Abstract][Full Text] [Related]
22. Challenges and perspectives in vaccination against leishmaniasis.
de Oliveira CI; Nascimento IP; Barral A; Soto M; Barral-Netto M
Parasitol Int; 2009 Dec; 58(4):319-24. PubMed ID: 19698801
[TBL] [Abstract][Full Text] [Related]
23. Multifunctional CD4⁺ T cells in patients with American cutaneous leishmaniasis.
Macedo AB; Sánchez-Arcila JC; Schubach AO; Mendonça SC; Marins-Dos-Santos A; de Fatima Madeira M; Gagini T; Pimentel MI; De Luca PM
Clin Exp Immunol; 2012 Mar; 167(3):505-13. PubMed ID: 22288594
[TBL] [Abstract][Full Text] [Related]
24. Cross-protection against Leishmania donovani but not L. Braziliensis caused by vaccination with L. Major soluble promastigote exogenous antigens in BALB/c mice.
Tonui WK; Titus RG
Am J Trop Med Hyg; 2007 Mar; 76(3):579-84. PubMed ID: 17360887
[TBL] [Abstract][Full Text] [Related]
25. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
Iborra S; Soto M; Carrión J; Alonso C; Requena JM
Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
[TBL] [Abstract][Full Text] [Related]
26. Identification and purification of immunogenic proteins from nonliving promastigote polyvalent Leishmania vaccine (Leishvacin ).
Cardoso SR; da Silva JC; da Costa RT; Mayrink W; Melo MN; Michalick MS; Liu IA; Fujiwara RT; Nascimento E
Rev Soc Bras Med Trop; 2003; 36(2):193-9. PubMed ID: 12806454
[TBL] [Abstract][Full Text] [Related]
27. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection.
Stober CB; Lange UG; Roberts MT; Alcami A; Blackwell JM
J Immunol; 2005 Aug; 175(4):2517-24. PubMed ID: 16081824
[TBL] [Abstract][Full Text] [Related]
28. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis.
Calvopina M; Barroso PA; Marco JD; Korenaga M; Cooper PJ; Nonaka S; Hashiguchi Y
Vaccine; 2006 Jul; 24(27-28):5645-52. PubMed ID: 16621179
[TBL] [Abstract][Full Text] [Related]
30. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK.
Pinto EF; Pinheiro RO; Rayol A; Larraga V; Rossi-Bergmann B
Infect Immun; 2004 Aug; 72(8):4521-7. PubMed ID: 15271911
[TBL] [Abstract][Full Text] [Related]
31. The role of TLR9 on Leishmania amazonensis infection and its influence on intranasal LaAg vaccine efficacy.
Pratti JES; da Fonseca Martins AM; da Silva JP; Ramos TD; Pereira JC; Firmino-Cruz L; Oliveira-Maciel D; Vieira TSS; Lacerda LL; Vale AM; Freire-de-Lima CG; Gomes DCO; Saraiva EM; Rossi-Bergmann B; de Matos Guedes HL
PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007146. PubMed ID: 30802247
[TBL] [Abstract][Full Text] [Related]
32. The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity to L. major.
Kemp M; Handman E; Kemp K; Ismail A; Mustafa MD; Kordofani AY; Bendtzen K; Kharazmi A; Theander TG
FEMS Immunol Med Microbiol; 1998 Mar; 20(3):209-18. PubMed ID: 9566492
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of intranasal LaAg vaccine against Leishmania amazonensis infection in partially resistant C57Bl/6 mice.
Pratti JE; Ramos TD; Pereira JC; da Fonseca-Martins AM; Maciel-Oliveira D; Oliveira-Silva G; de Mello MF; Chaves SP; Gomes DC; Diaz BL; Rossi-Bergmann B; de Matos Guedes HL
Parasit Vectors; 2016 Oct; 9(1):534. PubMed ID: 27716449
[TBL] [Abstract][Full Text] [Related]
34. Total Leishmania antigens with Poly(I:C) induce Th1 protective response.
Sanchez MV; Eliçabe RJ; Di Genaro MS; Germanó MJ; Gea S; García Bustos MF; Salomón MC; Scodeller EA; Cargnelutti DE
Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28901553
[TBL] [Abstract][Full Text] [Related]
35. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis.
Pérez-Jiménez E; Kochan G; Gherardi MM; Esteban M
Microbes Infect; 2006 Mar; 8(3):810-22. PubMed ID: 16504562
[TBL] [Abstract][Full Text] [Related]
36. T-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy.
Da-Cruz AM; Bittar R; Mattos M; Oliveira-Neto MP; Nogueira R; Pinho-Ribeiro V; Azeredo-Coutinho RB; Coutinho SG
Clin Diagn Lab Immunol; 2002 Mar; 9(2):251-6. PubMed ID: 11874860
[TBL] [Abstract][Full Text] [Related]
37. Cross-protective efficacy of Leishmania infantum LiHyD protein against tegumentary leishmaniasis caused by Leishmania major and Leishmania braziliensis species.
Lage DP; Martins VT; Duarte MC; Costa LE; Tavares GSV; Ramos FF; Chávez-Fumagalli MA; Menezes-Souza D; Roatt BM; Tavares CAP; Coelho EAF
Acta Trop; 2016 Jun; 158():220-230. PubMed ID: 26976272
[TBL] [Abstract][Full Text] [Related]
38. Can interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection?
Gomes-Silva A; de Cássia Bittar R; Dos Santos Nogueira R; Amato VS; da Silva Mattos M; Oliveira-Neto MP; Coutinho SG; Da-Cruz AM
Clin Exp Immunol; 2007 Sep; 149(3):440-4. PubMed ID: 17614975
[TBL] [Abstract][Full Text] [Related]
39. Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia.
Vélez ID; Gilchrist K; Arbelaez MP; Rojas CA; Puerta JA; Antunes CM; Zicker F; Modabber F
Trans R Soc Trop Med Hyg; 2005 Aug; 99(8):593-8. PubMed ID: 15893351
[TBL] [Abstract][Full Text] [Related]
40. Leishmania (Leishmania) amazonensis-induced cutaneous leishmaniasis in the primate Cebus apella: a model for vaccine trials.
Garcez LM; Goto H; Ramos PK; Brigido Mdo C; Gomes PA; Souza RA; De Luca PM; Mendonça SC; Muniz JA; Shaw JJ
Int J Parasitol; 2002 Dec; 32(14):1755-64. PubMed ID: 12464422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
